KBI Biopharma Acquires Biologics Operations in Colorado
News May 13, 2014
KBI Biopharma, Inc. (KBI) has signed an agreement with Merck & Co., Inc. (known as Merck in the United States and Canada) to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014.
Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third party customers.
“We are very pleased to continue to advance our partnership with Merck, and to welcome this very highly regarded team of scientists in Boulder to the KBI team,” stated Joe McMahon, KBI’s President and CEO.
McMahon continued, “KBI will now offer expanded microbial development and manufacturing services up to 1500L scale, as well as continuing to offer our current full range of process development, analytical and formulation development and mammalian manufacturing services up to 2000L.”
KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.
To date, KBI has helped to advance more than 220 molecules in 55 unique health indications for over 170 clients around the world.
With the addition of these expanded microbial capabilities, KBI is well positioned to continue to accelerate an even broader range of drug development programs for its global client base.
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
23rd World Congress on Pediatrics, Neonatology & Primary Care
Nov 22 - Nov 23, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019